What Has Been The Historical And Current Growth Of The Viral Inactivation Market?
The viral inactivation market has seen considerable growth due to a variety of factors.
•In the past few years, the viral inactivation market has experienced a robust growth. It is projected to expand from $5.01 billion in 2024 to $5.48 billion in 2025, representing a compound annual growth rate (CAGR) of 9.4%.
Factors such as global air traffic growth, improved navigation capabilities, expansion of commercial aviation, cost savings in the airline industry, enhanced flight safety, and decrease in pilot workload have all contributed to the growth observed in the historic period.
What Is The Forecast For The Viral Inactivation Market By 2029?
The viral inactivation market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the viral inactivation market is anticipated to experience swift expansion, reaching a value of "$8.28 billion in 2029 with a CAGR of 10.9%.
This surge during the forecast period can be linked to the evolution of autonomous flight, new-age aircraft designs, endeavours for eco-friendly aviation, urban air mobility (UAM), and the growing need for aircraft. The forecast period is also expected to witness trends such as the inclusion of sophisticated avionics, the application of artificial intelligence, innovations in human-machine interface (HMI), retrofitting of current aircraft, and the introduction of a global navigation satellite system (GNSS).
What Are The Essential Drivers Behind The Growth Of The Viral Inactivation Market?
The escalation in the emergence of diverse infectious diseases is projected to fuel the viral inactivation market's growth trajectory. These diseases, which transmit through tainted food and drinks, and pathogens like bacteria, viruses, fungi, and parasites, necessitate the use of viral inactivation. This technique is extensively used in managing human diseases to neutralize viruses via physical and chemical disinfectants, thereby thwarting the dissemination of infectious viral diseases and escalating the growth of the viral inactivation market. Such an instance was recorded in March 2024 when the Centers for Disease Control and Prevention, a stateside public health agency, reported that the count of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. The rate also spiked from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Consequently, the burgeoning frequency of various infectious diseases bolsters the expansion of the viral inactivation market.
How Is The Global Viral Inactivation Market Divided Into Key Segments?
The viral inactivation market covered in this report is segmented –
1) By Product: Kits And Reagents, Systems, Services
2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods
3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users
Subsegments:
1) By Kits And Reagents: Viral Inactivation Kits, PCR Reagents, Antibodies and Enzymes
2) By Systems: Automated Viral Inactivation Systems, Batch Viral Inactivation Systems, Continuous Flow Systems
3) By Services: Viral Testing Services, Validation Services, Consulting Services
Pre-Book The Viral Inactivation Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Viral Inactivation Market?
The viral inactivation market is experiencing a significant upward trend driven by the increasing adoption of sophisticated processes. In order to maintain their competitive edge, firms in this sector are incorporating these state-of-the-art methods into their operations. A prime example of this is WuXi Advanced Therapies, a fully-owned subsidiary of WuXi AppTec, a biopharmaceutical firm based in China. In March 2022, the company introduced a new technology known as Tetracycline-Enabled Self-Silencing Adenovirus (TESSA). This innovative technology allows the company to concurrently execute all assay formulation, biosafety, viral clearance, product release, and testing within their own organization. Notably, this method offers an entirely novel way to produce adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade, eliminating the necessity for transfection.
Who Are the Key Players in the Viral Inactivation Market?
Major companies operating in the viral inactivation market include:
• Merck & Co. Inc.
• Sartorius AG
• Texcell SA
• SGS SA
• Charles River Laboratories Inc.
• Clean Cells SAS
• Rad Source Technologies
• WuXi AppTec
• Sigma-Aldrich Co. LLC
• Thermo Fisher Scientific Inc.
• Macopharma
• Cerus Corporation
• TERUMO BCT INC.
• Shandong Weigao Group Medical Polymer Co. Ltd.
• Pall Corporation And Eurofins Scientific
• General Electric Company
• Cytiva
• Mettler Toledo
• Viral Inactivated Plasma Systems SA
• Eurofins Scientific SE
• Lonza Group AG
• Avantor Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche AG
• Fujifilm Holdings Corporation
• Pfizer Inc.
• Novartis AG
• Gilead Sciences Inc.
• Johnson & Johnson Private Limited
What are the Regional Insights into the Viral Inactivation Market?
North America was the largest region in the viral inactivation market in 2024. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
